336 related articles for article (PubMed ID: 30511964)
1. Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression.
Song B; Park SH; Zhao JC; Fong KW; Li S; Lee Y; Yang YA; Sridhar S; Lu X; Abdulkadir SA; Vessella RL; Morrissey C; Kuzel TM; Catalona W; Yang X; Yu J
J Clin Invest; 2019 Feb; 129(2):569-582. PubMed ID: 30511964
[TBL] [Abstract][Full Text] [Related]
2. TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
Paller C; Pu H; Begemann DE; Wade CA; Hensley PJ; Kyprianou N
Prostate; 2019 Jan; 79(1):31-43. PubMed ID: 30155899
[TBL] [Abstract][Full Text] [Related]
3. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.
Wang X; Brea L; Lu X; Gritsina G; Park SH; Xie W; Zhao JC; Yu J
Oncogene; 2022 Sep; 41(37):4259-4270. PubMed ID: 35931888
[TBL] [Abstract][Full Text] [Related]
7. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 reprograms the TGF-β-stimulated transcriptional program from a metastasis promoter to a tumor suppressor in nasopharyngeal carcinoma.
Li J; Wang W; Chen S; Cai J; Ban Y; Peng Q; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Yi M; Xiang B
Cancer Lett; 2019 Feb; 442():1-14. PubMed ID: 30392786
[TBL] [Abstract][Full Text] [Related]
9. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
10. Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis.
Pu H; Begemann DE; Kyprianou N
Endocrinology; 2017 Jun; 158(6):1612-1622. PubMed ID: 28324007
[TBL] [Abstract][Full Text] [Related]
11. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).
Choi JD; Kim TJ; Jeong BC; Jeon HG; Jeon SS; Kang MY; Yeom SY; Seo SI
Sci Rep; 2021 Nov; 11(1):21984. PubMed ID: 34753990
[TBL] [Abstract][Full Text] [Related]
12. Sox5 contributes to prostate cancer metastasis and is a master regulator of TGF-β-induced epithelial mesenchymal transition through controlling Twist1 expression.
Hu J; Tian J; Zhu S; Sun L; Yu J; Tian H; Dong Q; Luo Q; Jiang N; Niu Y; Shang Z
Br J Cancer; 2018 Jan; 118(1):88-97. PubMed ID: 29123266
[TBL] [Abstract][Full Text] [Related]
13. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
14. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
15. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Li S; Fong KW; Gritsina G; Zhang A; Zhao JC; Kim J; Sharp A; Yuan W; Aversa C; Yang XJ; Nelson PS; Feng FY; Chinnaiyan AM; de Bono JS; Morrissey C; Rettig MB; Yu J
Cancer Res; 2019 May; 79(10):2580-2592. PubMed ID: 30952632
[TBL] [Abstract][Full Text] [Related]
16. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
[TBL] [Abstract][Full Text] [Related]
19. Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1.
Wang L; Xu M; Kao CY; Tsai SY; Tsai MJ
J Clin Invest; 2020 Apr; 130(4):1782-1792. PubMed ID: 31874106
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
